Holen Sie sich die Stockscreener-App
149.99
0.77%
-1.17
Vorhandelsmarkt:
149.99
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BDX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$151.16
Offen:
$150.01
24-Stunden-Volumen:
1.93M
Relative Volume:
0.70
Marktkapitalisierung:
$41.33B
Einnahmen:
$21.37B
Nettoeinkommen (Verlust:
$1.41B
KGV:
38.03
EPS:
3.9437
Netto-Cashflow:
$3.07B
1W Leistung:
+3.21%
1M Leistung:
+0.37%
6M Leistung:
-20.85%
1J Leistung:
-13.53%
1-Tages-Spanne:
$149.04
$151.02
1-Wochen-Bereich:
$143.13
$153.24
52-Wochen-Spanne:
$141.82
$213.08
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
149.99 | 41.65B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
418.61 | 149.48B | 10.58B | 3.00B | 2.83B | 8.2437 |
ALC
Alcon Inc
|
66.11 | 32.58B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.80 | 28.42B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
193.14 | 28.44B | 5.54B | 1.52B | 1.74B | 10.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Fortgesetzt | Goldman | Neutral |
| 2026-02-10 | Fortgesetzt | Barclays | Overweight |
| 2026-02-03 | Fortgesetzt | Citigroup | Buy |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
Becton, Dickinson and Company: - marketscreener.com
Becton, Dickinson and Company (BDX) Stock Analysis: Unpacking a 19.89% Potential Upside - DirectorsTalk Interviews
Jim Cramer on Becton, Dickinson: “I Think You Buy Some and Then You Wait” - insidermonkey.com
Becton Dickinson earnings loom as investors eye post-divestiture growth By Investing.com - Investing.com
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Deals tracker: Tennessee senior care operator spends $50M for 5 facilities - Modern Healthcare
Is It Smart To Buy Becton, Dickinson and Company (NYSE:BDX) Before It Goes Ex-Dividend? - Yahoo Finance
BDX Technical Analysis | Trend, Signals & Chart Patterns | BECTON DICKINSON AND CO (NYSE:BDX) - ChartMill
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
June 3, 2026Polen Thomas E Jr - Becton Dickinson
Becton Dickinson chairman, CEO Thomas E. Polen Jr. sells $404k in shares - Investing.com UK
Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider - GlobeNewswire Inc.
June 2, 2026Menziuso Peter3 - Becton Dickinson
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co stock (US0758871091): Norges Bank stake highlights interest after recent earni - AD HOC NEWS
Becton, Dickinson And Company (BDX) Stock Analysis: Exploring A 23% Upside Potential - DirectorsTalk Interviews
TD Cowen Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $163 - 富途牛牛
Becton Dickinson resumes U.S. shipments of ChloraPrep after additional testing - TradingView
Here’s Hinde Group’s Updates on Becton, Dickinson and Company (BDX) - Insider Monkey
Piper Sandler Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $161 - Moomoo
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Becton Dickinson EVP Michael Feld sells $11,051 in stock - Investing.com UK
Becton Dickinson EVP Michael Feld sells $11,051 in stock By Investing.com - Investing.com UK
Goldman Sachs Adjusts PT on Becton, Dickinson and Co. to $150 From $156, Maintains Neutral Rating - Moomoo
Becton, Dickinson And Company (BDX): Evaluating Growth Potential With A 24% Upside - DirectorsTalk Interviews
Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story - simplywall.st
Becton, Dickinson & Co. Faces Valuation Shift Amid Declining Stock Returns and High Debt - Markets Mojo
BD Delivers Kidney Stone Care for Urology Teams with the Elyra Thulium Fiber Laser System - Finviz
New BD laser targets smoother, quieter kidney stone care procedures - Stock Titan
Becton Dickinson and Co stock (US0758871091): new €600 million notes and recent loss raise questio - AD HOC NEWS
Becton, Dickinson and Company (BDX) Announces €600 Million Notes Offering - GuruFocus
Becton Dickinson Euro Finance Issues €600 Million 3.855% Notes Due 2033 Guaranteed by BD - Minichart
Becton Dickinson subsidiary issues €600 million in 3.855% notes due 2033 - Investing.com Canada
Becton Dickinson Issues €600 Million 3.855% Notes Due 2033 to Refinance 2026 Debt - TradingView
A Look at Becton Dickinson & Co (BDX) After 3.2% Gain -- GF Value $194.45 vs Price $146.95 - GuruFocus
Nebulizers - GlobeNewswire Inc.
Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock? - Barchart.com
BD Names Peter Menziuso to Lead $BD Interventional Business - citybiz
Becton, Dickinson and Company Appoints Peter Menziuso as Executive Vice President and President, Bd Interventional, Effective June 1, 2026 - marketscreener.com
Becton, Dickinson and Company (BDX) Stock Analysis: Unveiling a 27.75% Potential Upside - DirectorsTalk Interviews
Becton Dickinson hikes profit outlook, names CFO - MSN
Becton Dickinson and Co stock (US0758871091): earnings beat and strategic focus keep medtech giant i - AD HOC NEWS
DNB Asset Management AS Has $22.28 Million Position in Becton, Dickinson and Company $BDX - MarketBeat
Northwestern Mutual Wealth Management Co. Increases Stock Position in Becton, Dickinson and Company $BDX - MarketBeat
Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target - Insider Monkey
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):